CheckImmune is an innovative immune biomarker CRO for preclinical and clinical programs. As a spin-off company of Charité Universitätsmedizin Berlin we have strong links to academic state-of-the art research. CheckImmune is providing biomarker studies with focus on novel immunotherapeutics (small molecules, biologics, Advanced Therapy Medicinal Products – ATMPs) and immunological challenges in other medical areas. CheckImmune is specialized in the development and validation of immunological biomarkers for global clinical trials and accredited according to ISO 17025 and 15189 with fulfilling the requirements of GCLP (Good Clinical Laboratory Practice). Our core expertise includes assay development and validation for Receptor Occupancy, Flow Cytometry, Multiplex Cytokine Analyses, Functional Tests, Single Cell Multiomics, and Tissue Biopsies. We are a certified service provider for 10x Genomics, Olink, and ProteinSimple Ella. We are a team of well recognized experts for immune biomarker analyses and data interpretation. Our Services are Selection/validation of drug lead candidates, Phase 0 studies with access to fresh patient material, Therapy monitoring (safety, efficacy/stratification) and Data analysis and scientific & medical interpretation. At CheckImmune, we develop highly specialized immunological biomarker assays and provide end-to-end lab services for clinical and preclinical trials. From assay design to regulatory-grade data analysis – we help biopharma companies understand immune responses with precision. We are a certified service provider for 10x Genomics, OLINK and bio-techne. With a track record of more than 90 industry-sponsored trials and 120,000 samples we have earned an excellent international reputation. Selection/validation of drug lead candidates Application of a broad panel of customized and off-the-shelf biomarker tests using cutting-edge technologies for lead candidate selection. Phase 0 studies with access to fresh patient material Proof-of-concept studies on biosamples from target patient populations (phase 0) to develop and confirm selected biomarker test portfolios for following therapy monitoring. Therapy monitoring Therapy monitoring in clinical trials to check safety, PD/PK, patient stratification with a wide range of validated assays as well as newly developed customized methods. Data analysis and scientific & medical interpretation CheckImmune is backed by a world-renowned team of experts with years of academic and commercial experience in the field of immune biomarkers. Technology used Our Technology platforms are – Complex Flow & Spectral Cytometry – Molecular & Multi-Omics Analysis: Bulk RNAseq, TCR /BCR repertoire, Single cell Multiomics (RNAseq, TCRseq, CITEseq) Spatial multi-omics, qRT- PCR (e.g. IFN signature) and digitalPCR – Multiplex Ligand Assays (MSD, Ella, OLINK) – Functional Assays – Anti-Drug Response (ADA/ADT)
Changzhou Smart-Lifesciences Biotechnology Co.,Ltd.
Smart Lifesciences develops innovative scientific products and provides professional one-stop solutions. Our technology platform originated in chromatography and has been applied across the broad field of protein science-from protein preparation to purification, detection, and application development services. For large-scale manufacturing, our active DMF filings enable a seamless workflow to accelerate the translation of research.
BloodScan Biotech Inc.
BloodScan Biotech Inc. is a biotechnology company dedicated to precision oncology. Founded through technology transfer from a research team at the University of Michigan, BloodScan focuses on advancing innovations in liquid biopsy with the goal of becoming a key global driver in early cancer detection and disease monitoring. Our flagship product, Labyrinth One, is the world’s only liquid biopsy system capable of achieving tissue-biopsy-comparable performance. The system enables stable, fully automated enrichment of circulating tumor cells (CTCs) and delivers ultra-sensitive capabilities for early cancer screening and monitoring. Three Core Advantages: 1. Reliable CTC Isolation and Monitoring in Advanced Cancer – Enables disease monitoring and treatment response assessment in late-stage patients. 2. Tissue-Biopsy-Comparable Performance – Provides accuracy and biological integrity comparable to conventional histopathology. 3. Ultra-Sensitive Early Cancer Screening – Enhances early cancer detection rates to support more precise and timely treatment decisions. Our vision is to establish CTCs as a central pillar of next-generation cancer diagnostics, empowering healthcare systems worldwide to deliver earlier, more precise, and more personalized cancer care. | BloodScan Biotech Inc. Pioneering Liquid Biopsy for Precision Oncology BloodScan Biotech Inc. is a biotechnology company at the forefront of next-generation liquid biopsy technologies, committed to transforming cancer diagnostics through precision medicine. Established in 2023 as a spin-off from the University of Michigan, BloodScan focuses on advancing circulating tumor cell (CTC) isolation to improve early cancer detection, real-time treatment monitoring, and personalized therapeutic decision-making. The heart of BloodScan’s innovation is the Labyrinth One – Automated CTC Enrichment System, a compact, benchtop platform designed for high-throughput, label-free isolation of viable CTCs directly from blood samples. Unlike traditional antibody-based capture technologies, Labyrinth One utilizes microfluidic separation to deliver exceptional purity, recovery, and reproducibility—all within a 15-minute workflow. This allows for seamless integration into both clinical and research laboratory settings, enabling routine use of CTCs for diagnostics and translational oncology research. BloodScan’s mission is to bridge the gap between academic innovation and clinical implementation. Through strategic partnerships with research institutes, oncology centers, and clinical laboratories, the company aims to accelerate the adoption of liquid biopsy technologies and expand access to non-invasive cancer diagnostics that can meaningfully improve patient outcomes.
BIOTECHNOLOGY VALLEY
The Biotechnology Industrialists’ Association (BİYOSAD) aims to drive human development via innovative, high value-added products and services and is establishing the Biotechnology Valley within the Biotechnology Specialized Industrial Zone (BİOSB) in Istanbul. This project aspires to situate Turkey among the world’s leading biotechnology hubs. Biotechnology Valley, positioned in strategically located Tuzla, Istanbul, is a comprehensive initiative designed to create a specialized biotechnology ecosystem. The project aims to boost Turkey’s global presence in the biotechnology market through strong collaborations between business, academia, and the government. It spans 2.7 million square meters and will feature technology development zones, R&D centers, testing and calibration labs, patent offices, and specialized biotechnology schools. Our goal is to enhance global export potential by fostering domestic production of high value-added biotechnology products. We prioritize guiding industry and academia toward innovative collaboration, exploring nature’s possibilities in light of science. Our mission extends beyond meeting current demands to making a positive impact for future generations through sustainable and collaborative efforts. Biotechnology Valley is dedicated to enabling breakthrough technologies in the sector and hosting research that benefits society, adding value to both science and business. We are committed to providing a safe, innovative, and supportive business environment for all sector stakeholders. Join us as a partner in transforming Türkiye and the world into a leading biotechnology center. | Biotechnology Valley is a strategic technology and innovation ecosystem established under the leadership of the Biotechnology Industrialists Association (BIYOSAD) to lead Türkiye’s vision in biotechnology across science, technology, and production. Bringing together the public sector, industry, academia, and investors, the Valley aims to build a high–value-added, sustainable, and globally competitive biotechnology infrastructure. Located in Tepeören, Istanbul, and spanning approximately 2.7 million square meters, Biotechnology Valley is one of Türkiye’s most comprehensive biotechnology initiatives. With its advanced R&D centers, technology development zones, modern manufacturing facilities, and shared infrastructure, the Valley is designed as an integrated hub for local and international companies operating in pharmaceuticals, biotechnology products, medical technologies, and advanced life sciences. Biotechnology Valley is not only a center for production and R&D, but also a living and innovation ecosystem with sustainability at its core. The project prioritizes energy-efficient infrastructure, renewable energy solutions, water efficiency practices, integrated waste management systems, and comprehensive strategies to reduce carbon footprint. This approach positions biotechnology production in harmony with nature and with a strong sense of responsibility toward future generations. The Valley offers a collaborative, innovative, and scalable ecosystem for a wide range of stakeholders, from start-ups and research institutions to global players and investment funds. Through its open innovation approach, Biotechnology Valley promotes knowledge sharing and co-creation, aiming to integrate Türkiye’s biotechnology potential into the global value chain. With its robust infrastructure, sustainability-driven framework, and international vision, Biotechnology Valley continues to advance with determination toward becoming a regional and global center for biotechnology.